NCT07229742

A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-2173 Injection in Patients With Active Lupus Nephritis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 51 (estimated)
• Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The study is a Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in patients with lupus nephritis (LN). It adopts a randomized, double-blind, placebo-controlled, multicenter trial design.

Conditions

• Active Lupus Nephritis

Interventions

Type	Name	Description
DRUG	SHR-2173 Injection	SHR-2173 injection.
DRUG	SHR-2173 Injection Blank Preparation	SHR-2173 injection blank preparation.

Timeline

• Start date: 2025-11-22
• Primary completion: 2027-06-01
• Completion: 2028-03-01
• First posted: 2025-11-17
• Last updated: 2025-12-01

Locations

1 site across 1 country: China